The Johns Hopkins Cervical Dysplasia Center focuses on the management and prevention of cervical HPV disease. If you have had an abnormal Pap smear, obstetricians and gynecologists at our center are available for gynecologic checkups and second opinion visits, as well as evaluation to determine if you are a good candidate for clinical trial participation.
Request an Appointment
Before making an appointment, please fax a copy of your most recent pathology report to 443-769-1205. Then, call 443-997-0400 to get set up in the Johns Hopkins system.
Once you are in the system and have your records sent, you can contact our office below to set up an appointment:
We are interested in how immune responses occur in the cervix. The focus of our translational research is on developing immune therapies for disease caused by human papillomavirus (HPV). HPV infection causes more cancers than any other virus in the world.
Cervical cancer is the most common cancer caused by HPV, and although we have known how to screen for it for over half a century, it remains the second most common cause of cancer death in women. Although the preventive vaccines are a public health milestone, they prevent HPV infections, but are not designed to make immune responses to treat HPV.
We are testing different strategies to make immune responses that could treat HPV disease.
Clinical Trials
Artesunate intravaginal inserts or ointment for the treatment of high grade dysplasia in patients with persistent recurrence of HPV disease of the lower ano-genital tract
OVERVIEW
This is a compassionate use protocol for patients with persistent recurrence of HPV-associated disease of the lower ano-genital tract, and/or who have high grade squamous intraepithelial lesions (HSIL) at multiple body sites after standard-of-care surgical treatments can be enrolled in this expanded-access protocol.
This expanded access protocol includes two categories of patients: (1) patients who have already undergone multiple surgical procedures, and still have recurrence of their high grade dysplasia; and (2) patients who have extensive high grade dysplasia (HSIL) at more than one anatomic site, including vaginal, vulvar, cervical, or peri-anal.
